Skip to content

NanoViricides picks COVID-19 drug candidate, shares up

September 16, 2020

NanoViricides (NYSEMKT:NNVC) perks up 7% premarket on light volume in reaction to its announcement that it has selected a drug candidate, dubbed NV-CoV-1-R, for the treatment of COVID-19.

The company says NV-CoV-1-R consists of a nanoviricide, NV-CoV-1 with Gilead Sciences’ (NASDAQ:GILD) remdesivir encapsulated inside its core, adding that NV-CoV-1 is designed to attack the virus particles themselves and “possibly” would also attack infected cells that express a coronavirus antigen called S-protein. Normal cells, which would not display the S-protein, would be unaffected. The encapsulation of remdesivir, it claims, may protect it from rapid metabolism, increasing its stability and effectiveness.

Clinical trials are planned.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: